# Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis

> **NCT06048224** · PHASE3 · COMPLETED · sponsor: **Zhejiang Hisun Pharmaceutical Co. Ltd.** · enrollment: 669 (actual)

## Conditions studied

- Moderate to Severe Active Rheumatoid Arthritis

## Interventions

- **DRUG:** HS628+MTX
- **DRUG:** Actemra +MTX

## Key facts

- **NCT ID:** NCT06048224
- **Lead sponsor:** Zhejiang Hisun Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-28
- **Primary completion:** 2021-09-14
- **Final completion:** 2022-01-31
- **Target enrollment:** 669 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06048224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06048224, "Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06048224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*